Lirentelimab

• CAT Number: I042222
• CAS Number: 2283348-97-8
• Purity: ≥95%

Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis[1].
Monovalent Lirentelimab fragment antigen-binding (fab) binds to recombinant SIGLEC8 extracellular domain (ECD) is determined to be 464 pM[1].
Lirentelimab shows high affinity to SIGLEC8 in vitro, to SIGLEC8 expressed on eosinophils, and to NK cells via its Fc region in human blood[1].
Lirentelimab (1 µg/mL) selectively binds to eosinophils in human peripheral blood, and eosinophils and mast cells from human lung tissue[1].
Lirentelimab (0.0001-100 μg/mL; 30 min) induces apoptosis of IL-5-activated eosinophils[1].
Lirentelimab (30 min) shows potent antibody-dependent cell-mediated cytotoxicity (ADCC) Activity on human eosinophils with an EC50 value of 1.9 ng/mL to eosinophils in peripheral blood leukocytes (PBL) preparations from healthy donors[1].
Lirentelimab reduces eosinophil numbers in ex vivo human tissue[1].
Lirentelimab (100 μg; i.v. once) significantly inhibits IgE-mediated mast cell activation in a mice model of systemic anaphylaxis[1].

Reference

[1]. Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. Int Arch Allergy Immunol. 2019;180(2):91-102.
 [Content Brief]